**Table S8 Adjusted mean change from baseline in quality of life scores at 24 and 52 weeks (ITT analysis)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Abatacept (n=213)** | **Placebo (n=211)** | **Adjusted mean difference (95% CI)** |
| 24 weeks  |
| SF-36  PCS MCS | n=1245.11 (3.86 to 6.36)2.56 (0.93 to 4.18) | n=973.69 (2.30 to 5.08)2.62 (0.80 to 4.44) | 1.42 (–0.32 to 3.15**)**–0.06 (–2.32 to 2.20) |
| DLQI   | n=126–2.49 (–3.32 to –1.66) | n=98–0.71 (–1.64 to 0.23) | –1.78 (–2.94 to –0.63) |
| 52 weeks |
| SF-36  PCS MCS | n=1676.25 (4.97 to 7.52)3.89 (2.48 to 5.30) | n=1665.91 (4.61 to 7.22)2.73 (1.28 to 4.18) | Not calculatedNot calculated |
| DLQI  | n=167–2.49 (–3.24 to –1.75) | n=166–1.82 (–2.59 to –1.05)  | Not calculated |

Data are adjusted mean change (95% CI) unless indicated otherwise.

n is the number of patients with post-baseline and baseline measurements.

For early escape patients, the measurements at week 24 were set to missing.

At week 52, data are for double-blind and open-label periods combined, and treatment groups represent treatment received in the double-blind period; for early escape patients, day 365 corresponds to day 309 from start of open-label study medication (day 197 in open-label period).

CI, confidence interval; DLQI, Dermatology Life Quality Index; MCS, mental component summary; PCS, physical component summary; SF-36, Short Form-36.